Schnoll-Sussman Felice, Niec Rachel, Katz Philip O
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, 1315 York Avenue, New York City, NY 10021, USA.
Division of Gastroenterology and Hepatology, Weill Cornell Medicine, 1315 York Avenue, New York City, NY 10021, USA.
Gastrointest Endosc Clin N Am. 2020 Apr;30(2):239-251. doi: 10.1016/j.giec.2019.12.005. Epub 2020 Jan 13.
Proton pump inhibitors (PPIs) continue to be the medication of choice for treatment of acid-related disease, with few if any overt side effects seen with daily use. They are often prescribed empirically, often in high doses and with many patients being treated with multiple PPIs without an objective diagnosis. Therefore, they are believed to be overprescribed and used without indication. In this article we discuss the appropriate clinical indications for PPIs, review in detail the major associated adverse events, and put in perspective key issues in balancing benefits and risk of this exceptional (and safe) class of drug.
质子泵抑制剂(PPIs)仍然是治疗酸相关性疾病的首选药物,日常使用时几乎没有明显副作用。它们常常是经验性用药,剂量往往很高,而且许多患者在没有客观诊断的情况下同时使用多种质子泵抑制剂进行治疗。因此,人们认为它们存在过度处方和无适应证用药的情况。在本文中,我们讨论质子泵抑制剂的适当临床适应证,详细回顾主要的相关不良事件,并正确看待在平衡这类特殊(且安全)药物的获益与风险方面的关键问题。